Yahoo Web Search

Search results

    • AbbVie Completes Acquisition of Landos Biopharma

      Valley City Times Record· 21 hours ago

      With the completion of the acquisition, Landos is now part of AbbVie. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like ...

    • Signals From Our Investing Notebook

      Signals From Our Investing Notebook

      TheStreet.com· 6 days ago

      Another week has gone by and we’ve uncovered an ample number of confirming articles and other reports. Another week has gone by and we’ve uncovered an...

    • Small Business - The Andalusia Star-News | The Andalusia Star-News

      The Andalusia Star-News· 20 hours ago

      AbbVie Completes Acquisition of Landos Biopharma PR Newswire NORTH CHICAGO, Ill., May 23, 2024 - Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative